Lapatinib (GW-572016) Ditosylate

Catalog No.S1028

Molecular Weight(MW): 925.46

Lapatinib (GW-572016) Ditosylate is a potent EGFR and ErbB2 inhibitor with IC50 of 10.8 and 9.2 nM in cell-free assays, respectively.

Cited by 75 Publications

Cell Metab, 2018, 28(6):817-832

PubMed: 30244971 ( click the link to review the publication )

Cancer Cell, 2016, 29(4):563-573

PubMed: 27070703 ( click the link to review the publication )

Cancer Cell, 2012, 21(4):488-503

PubMed: 22516258 ( click the link to review the publication )

Cell Rep, 2019, 28(9):2331-2344

PubMed: 31461650 ( click the link to review the publication )

J Clin Med, 2019, 8(12)

PubMed: 31847378 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(18):4566-4578

PubMed: 29895705 ( click the link to review the publication )

Cell Syst, 2018, 6(3):329-342

PubMed: 29550255 ( click the link to review the publication )

Mol Cancer Res, 2018, 16(5):894-908

PubMed: 29453318 ( click the link to review the publication )

Cancer Biol Ther, 2018, 19(10):921-933

PubMed: 29856687 ( click the link to review the publication )

Methods Mol Biol, 2018, 1788:251-268

PubMed: 29243084 ( click the link to review the publication )

Oncotarget, 2018, 9(9):8560-8572

PubMed: 29492217 ( click the link to review the publication )

Cancer Res, 2017, 77(20):5554-5563

PubMed: 28923853 ( click the link to review the publication )

Cell Syst, 2017, 5(2):105-118

PubMed: 28837809 ( click the link to review the publication )

Proteomics, 2017, 10.1002/pmic.201600335

PubMed: 28127872 ( click the link to review the publication )

Tumour Biol, 2017, 39(3):1010428317695028

PubMed: 28349782 ( click the link to review the publication )

Cancer Res, 2016, 76(20):6095-6106

PubMed: 27569217 ( click the link to review the publication )

Mol Cancer Ther, 2016, 15(10):2486-2497

PubMed: 27507850 ( click the link to review the publication )

Oral Oncology, 2016, 10.1016/j.oraloncology.2016.05.010

PubMed: ( click the link to review the publication )

BMC Cancer, 2016, 16:678

PubMed: 27558154 ( click the link to review the publication )

Cancer Invest, 2016, 34(9):424-430

PubMed: 27657189 ( click the link to review the publication )

Gut, 2015, 10.1136/gutjnl-2014-309026

PubMed: ( click the link to review the publication )

Sci Transl Med, 2015, 7(284):284ra57

PubMed: 25904741 ( click the link to review the publication )

Cancer Res, 2015, 10.1158/0008-5472.CAN-15-0370

PubMed: 25952648 ( click the link to review the publication )

Mol Cancer, 2015, 14:72

PubMed: 25889650 ( click the link to review the publication )
Mol Cancer, 2015, 10.1186/s12943-015-0345-x

PubMed: ( click the link to review the publication )

Oncogene, 2015, 34(9):1160-73

PubMed: ( click the link to review the publication )

Cell Death Dis, 2015, 6:e1699

PubMed: 25789974 ( click the link to review the publication )

Mol Oncol, 2015, 9(3):586-600

PubMed: 25435280 ( click the link to review the publication )

Toxicol Appl Pharmacol, 2015, 10.1016/j.taap.2015.05.001

PubMed: 25981168 ( click the link to review the publication )

Org Biomol Chem, 2015, 13(17):5006-11

PubMed: 25820099 ( click the link to review the publication )

Cell Cycle, 2015, 14(7):1059-69

PubMed: 25602630 ( click the link to review the publication )

Nat Commun, 2014, 5:3384

PubMed: 24594970 ( click the link to review the publication )

Proc Natl Acad Sci USA, 2014, 109(17):6584-9

PubMed: 22492965 ( click the link to review the publication )

Cancer Res, 2014, 10.1158/0008-5472.CAN-14-0844

PubMed: 25377473 ( click the link to review the publication )

Oncogene, 2014, 10.1038/onc.2014.153.

PubMed: 24909179 ( click the link to review the publication )

Oncogene, 2014, 10.1038/onc.2014.161.

PubMed: 24909170 ( click the link to review the publication )

Oncogene, 2014, 10.1038/onc.2014.106.

PubMed: 24747966 ( click the link to review the publication )

Oncogene, 2014, 10.1038/onc.2014.106.

PubMed: 24747966 ( click the link to review the publication )

Cancer Lett, 2014, 342(1):82-91

PubMed: 24001610 ( click the link to review the publication )

Cancer Lett, 2014, 342(1):82-91

PubMed: 24001610 ( click the link to review the publication )

Breast Cancer Res, 2014, 16(3):R45

PubMed: 24887236 ( click the link to review the publication )

Antimicrob Agents Chemother, 2014, 10.1128/AAC.02393-14

PubMed: 24663025 ( click the link to review the publication )

Mol Cell Biol, 2014, 34(20):3843-54

PubMed: 25113560 ( click the link to review the publication )

Drug Metab Dispos, 2014, 42(11):1851-7

PubMed: 25165131 ( click the link to review the publication )

J Mol Endocrinol, 2014, 52(2):223-34

PubMed: 24463098 ( click the link to review the publication )

PLoS One, 2014, 9(9):e106349

PubMed: 25238247 ( click the link to review the publication )

Genes Cancer, 2014, 5(7-8):261-72

PubMed: 25221644 ( click the link to review the publication )

Biores Open Access, 2014,

PubMed: ( click the link to review the publication )
Genes Cancer, 2014, 5(7-8):261-72

PubMed: 25221644 ( click the link to review the publication )

J Clin Invest, 2013, 123(2):682-99

PubMed: 23348745 ( click the link to review the publication )

Neuro Oncol, 2013, 10.1093/neuonc/not152

PubMed: 24343111 ( click the link to review the publication )

Cancer Lett, 2013, 340(1):43-50

PubMed: 23811285 ( click the link to review the publication )

Mol Pharmacol, 2013, 83(4):882-93

PubMed: 23371912 ( click the link to review the publication )

Drug Metab Dispos, 2013, 10.1124/dmd.113.054189

PubMed: 24335466 ( click the link to review the publication )

Invest New Drugs, 2013, 31(6):1458-65

PubMed: 24068620 ( click the link to review the publication )

Cell Cycle, 2013, 12(18):2978-91

PubMed: 23974111 ( click the link to review the publication )

Virginia Commonwealth University, 2013, 2013

PubMed: ( click the link to review the publication )

ACS Nano, 2012, 6(10):8525-35

PubMed: 22947044 ( click the link to review the publication )

Proc Natl Acad Sci USA, 2012, 109(17):6584-9

PubMed: 22492965 ( click the link to review the publication )

Oncogene, 2012, 32(37):4331-42

PubMed: 23085751 ( click the link to review the publication )

Cancer Lett, 2012, 316(1):77-84

PubMed: 22082529 ( click the link to review the publication )

Cancer Lett, 2012, 324(1):98-108

PubMed: 22579651 ( click the link to review the publication )

Mol Oncol, 2012, 7(3):392-401

PubMed: 23253899 ( click the link to review the publication )

Mol Carcinog, 2012, 52(12):959-69

PubMed: 22693070 ( click the link to review the publication )

Prostate, 2012, 72(10):1140-9

PubMed: 22127954 ( click the link to review the publication )

Anal Bioanal Chem, 2012, 403(6):1685-95

PubMed: 22526649 ( click the link to review the publication )

PLoS One, 2012, 7(5):e36691

PubMed: 22615792 ( click the link to review the publication )

Br J Cancer, 2011, 105(6):796-806

PubMed: 21847123 ( click the link to review the publication )

Mol Cancer Ther, 2011, 10(10):1846-56

PubMed: 21768330 ( click the link to review the publication )

Mol Cancer Ther, 2011, 10(4):697-707

PubMed: 21447712 ( click the link to review the publication )

Biochem Pharmacol, 2011, 82(10):1457-66

PubMed: 21664897 ( click the link to review the publication )

Anticancer Res, 2011, 31(11):3767-73

PubMed: 22110198 ( click the link to review the publication )
Int J Proteomics, 2011, 2011:215496

PubMed: 22091388 ( click the link to review the publication )

Carcinogenesis, 2010, 31(11):1948-55

PubMed: 20837598 ( click the link to review the publication )

Methods Mol Biol, 2010, 661:107-22

PubMed: 20811979 ( click the link to review the publication )

Purity & Quality Control

Choose Selective HER2 Inhibitors

Biological Activity

Description

Lapatinib (GW-572016) Ditosylate is a potent EGFR and ErbB2 inhibitor with IC50 of 10.8 and 9.2 nM in cell-free assays, respectively.

Targets

ErbB2 ^[1] (Cell-free assay)	EGFR ^[1] (Cell-free assay)	ErbB4 ^[1] (Cell-free assay)
9.2 nM	10.8 nM	367 nM

In vitro

Lapatinib Ditosylate weakly inhibits the activity of ErbB4 with IC50 of 367 nM, and displays >300-fold selectivity for EGFR and ErbB2 over other kinases such as c-Src, c-Raf, MEK, ERK, c-Fms, CDK1, CDK2, p38, Tie-2, and VEGFR2. Lapatinib Ditosylate significantly inhibits receptor autophosphorylation of EGFR and ErbB2 in a dose-dependent manner with IC50 of 170 nM and 80 nM, respectively in HN5 cells; as well as 210 nM and 60 nM, respectively in BT474 cells. Unlike OSI-774 and Iressa (ZD1839) which preferentially inhibit the growth of the EGFR-overexpressing cells, Lapatinib Ditosylate inhibits the growth of both EGFR- and ErbB2-overexpressing cells. Lapatinib Ditosylate displays higher inhibitory activity against EGFR- or ErbB2-overexpressing cells with IC50 of 0.09-0.21 μM, compared with cells expressing low levels of EGFR or ErbB2 with IC50 of 3-12 μM, and exhibits ~100-fold selectivity over the normal fibroblast cells. Lapatinib Ditosylate potently inhibits the outgrowth of EGFR-overexpressing HN5 and A-431 cells, as well as ErbB2-overexpressing BT474 and N87 cells, and significantly induces G1 arrest of HN5 cells and apoptosis of BT474 cells, which are associated with inhibition of AKT phosphorylation. ^[1]

Cell Data

Cell Lines	Assay Type	Incubation Time	Activity Description	PMID
HN5 cell line	NXrSUpdwWHKxbHnm[ZJifGmxbjDhd5NigQ>?		M4LKWWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iSF61JINmdGxibHnu[UwhUUN3ME2wMlAzPSEQvF2=	MnLKNVY1QDN5N{K=
BT474 cell line	MnezVJJwdGmoZYLheIlwdiCjc4PhfS=>		MnHmRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCEVES3OEBk\WyuIHzpcoUtKEmFNUC9NE4xOjVizszN	NXniUGJSOTZ2OEO3O\|I>
HN5 cell	NILLVlJIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		M4TENWlvcGmkaYTpc44hd2ZiSF61JINmdGxiZ4Lve5RpKGGodHXyJFczKGi{czygTWM2OD1yLkGyJO69VQ>?	NV7ocIhGOTZ5N{e0NVA>
BT474 cell	M{HwZWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NYjzcFQ4UW6qaXLpeIlwdiCxZjDCWFQ4PCClZXzsJIdzd3e2aDDh[pRmeiB5MjDodpMtKEmFNUC9NE4xQCEQvF2=	MoPONVY4Pzd2MUC=
N87 cell	MkPTS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		MnLUTY5pcWKrdHnvckBw\iCQOEegZ4VtdCCpcn;3eIgh[W[2ZYKgO\|IhcHK\|LDDJR\|UxRTBwMEig{txO	MVKxOlc4PzRzMB?=
HFF cell	NFPYXJhIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NW\rbod1UW6qaXLpeIlwdiCxZjDISmYh[2WubDDndo94fGhuIFnDOVA:QS57IN88US=>	NH\SVYgyPjd5N{SxNC=>
SKBR3 cells	NWLvSldvS3m2b4TvfIlkcXS7IHHzd4F6		M2DCVWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJHNMSlJ\|IHPlcIx{KGGodHXyJFczKGi{czDifUBUWkJiYYPzZZktKEmFNUC9NE4xOTdizszN	MkjkNVkxOjh2MkW=
A431 cells	MX3DfZRwfG:6aXPpeJkh[XO\|YYm=		M3\nb2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGE1OzFiY3XscJMh[W[2ZYKgO\|IhcHK\|IHL5JHNTSiCjc4PhfUwhUUN3ME2wMlExPCEQvF2=	MlS4NVk5QDh5NkG=
SKBR3 cells	Mm\zR5l1d3SxeHnjbZR6KGG\|c3H5		M2TpRWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJHNMSlJ\|IHPlcIx{KGGodHXyJFczKGi{czDifUBUWkJiYYPzZZktKEmFNUC9NE4xOjlizszN	MnXnNVk5QDh5NkG=
HepG2 cells	NH7pellRem:uaX\ldoF1cW:wIHHzd4F6		MWPBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEincFeyJINmdGy\|IHHmeIVzKGi{czDifUBCXFBiY3;ueIVvfCCjc4PhfUwhUUN3ME22MlI4KM7:TR?=	M3nIblIxOTR\|N{e4
Hep3B2 cells	NFzaVHpRem:uaX\ldoF1cW:wIHHzd4F6		NX23U3dJSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDI[ZA{SjJiY3XscJMh[W[2ZYKgbJJ{KGK7IFHUVEBkd262ZX70JIF{e2G7LDDJR\|UxRTVwNEmg{txO	NX7nW4w4OjBzNEO3O\|g>
SKHEP1 cells	NIHpfZNRem:uaX\ldoF1cW:wIHHzd4F6		NEHYcmNCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIGPLTGVROSClZXzsd{Bi\nSncjDodpMh[nliQWTQJINwdnSnboSgZZN{[XluIFnDOVA:PS5\|IN88US=>	NXrPWIxbOjBzNEO3O\|g>
MCF7 cells	NXW2eoZLWHKxbHnm[ZJifGmxbjDhd5NigQ>?		NVGwbY9wSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDNR2Y4KGOnbHzzJIFnfGW{IHjyd{BjgSCDVGCgZ49vfGWwdDDhd5NigSxiSVO1NF03NjZizszN	MnLxNlAyPDN5N{i=
MDA-MB-231 cells	NUC2OZFxWHKxbHnm[ZJifGmxbjDhd5NigQ>?		M{nZfWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTVTBMW1DNTJ\|MTDj[YxteyCjZoTldkBpenNiYomgRXRRKGOxboTlcpQh[XO\|YYmsJGlEPTB;NT60JO69VQ>?	NIPwRnQzODF2M{e3PC=>
SK-BR-3 cells	M3m1RXBzd2yrZnXyZZRqd25iYYPzZZk>		NYTjN5pLSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDTT{1DWi1\|IHPlcIx{KGGodHXyJIhzeyCkeTDBWHAh[2:wdHXueEBie3OjeTygTWM2OD1yLkC0JO69VQ>?	M1XPdVIxOTR\|N{e4
A431 cells	M4jIWmZ2dmO2aX;uJIF{e2G7		NVuwbIhoUW6qaXLpeIlwdiCxZjDFS2ZTKGmwdILhZ4VtdHWuYYKgdIhwe3Cqb4L5cIF1cW:wIHnuJIh2dWGwIFG0N\|Eh[2WubIOgZpkhTUyLU1GsJGlEPTB;MD6wOVIh\|ryP	M{HaNlIxOzR4NkW1
N87 cells	MVnGeY5kfGmxbjDhd5NigQ>?		M2HXdWlvcGmkaYTpc44hd2ZiRYLiRlIhcW62cnHj[YxtfWyjcjDwbI9{eGixconsZZRqd25iaX6gbJVu[W5iTki3JINmdGy\|IHL5JGVNUVODLDDJR\|UxRTBwMTFOwG0>	MXKyNFM1PjZ3NR?=
MIAPaCa cells	NIL3ZopHfW6ldHnvckBie3OjeR?=		NGezSoFKdmirYnn0bY9vKG:oIFXHSnIheGixc4Doc5J6dGG2aX;uJIlvKGi3bXHuJG1KSVCjQ3GgZ4VtdHNiYomgSWxKW0FuIFnDOVA:OC52M{Og{txO	MkDHNlA5OTd3MkO=
MIAPaCa cells	M37xVGZ2dmO2aX;uJIF{e2G7		NGX1bZlKdmirYnn0bY9vKG:oIFXSRoIzKHCqb4PwbI9zgWyjdHnvckBqdiCqdX3hckBOUUGSYVPhJINmdGy\|IHL5JGVNUVODLDDJR\|UxRTBwMUSg{txO	MmnONlA5OTd3MkO=
CAL27 cells	MlnWR5l1d3SxeHnjbZR6KGG\|c3H5		NXz5RWlpS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hS0GOMkegZ4VtdHNib4\ldoV5eHKnc4PpcochTUeIUjDifUBz\XOjeoXybY4h\HmnIILl[JVkfGmxbjDhd5NigSxiSVO1NF0xNjByNzFOwG0v	MU[yNVA5ODZ{OR?=
SKOV3 cells	NUO4XHRuS3m2b4TvfIlkcXS7IHHzd4F6		NES0cHFEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBUU0:YMzDj[YxteyCxdnXy[ZhxemW\|c3nu[{BJTVJ{IHL5JJJme2G8dYLpckBlgWVicnXkeYN1cW:wIHHzd4F6NCCLQ{WwQVAvODB\|IN88UU4>	NWTnOFJlOjFyOEC2Nlk>
CAL27 cells	NXPSb5Z1TnWwY4Tpc44h[XO\|YYm=	MnrsNVYhcA>?	NFK4SHZKdmirYnn0bY9vKG:oIFXHSk1qdmS3Y3XkJGVITlJicHjvd5Bpd3K7bHH0bY9vKGmwIHj1cYFvKEODTEK3JINmdGy\|IH;2[ZJmgHC{ZYPzbY5oKEWJRmKgZYZ1\XJiMU[gbJJ{KGK7IGfld5Rmem5iYnzveEwhUUN3ME2wMlA{OiEQvF2=	M1zMZlIyODhyNkK5
SK-BR-3 cells	M{XtZnBzd2yrZnXyZZRqd25iYYPzZZk>		M3zIdWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgSZJjSjJib4\ldoV5eHKnc4PpcochcHWvYX6gV2suSlJvMzDj[YxteyCkeTDNWHQh[XO\|YYmsJGlEPTB;MD6wN\|Ih\|ryP	Mo\aNlE2PzB6NEO=
BXF T24 cells	NHzaRohEgXSxdH;4bYNqfHliYYPzZZk>	MWS0JIRigXN?	M{\FT2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGJZTiCWMkSgZ4VtdHNiYX\0[ZIhPCCmYYnzJIJ6KHC{b4Dp[Il2dSCrb3Tp[IUhe3SjaX7pcocu[mG\|ZXSg[ox2d3KxbXX0dolkKGGwYXz5d4l{NCCLQ{WwQVkvPjVizszN	NFjzN3UzOjF4OU[wNS=>
CXF 269L cells	NYDYc5lbS3m2b4TvfIlkcXS7IHHzd4F6	NVq5OVVlPCCmYYnz	NFzPeZREgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBEYEZiMk[5UEBk\WyuczDh[pRmeiB2IHThfZMh[nlicILvdIllcXWvIHnv[Ill\SC\|dHHpcolv\y2kYYPl[EBndHWxcn;t[ZRzcWNiYX7hcJl{cXNuIFnDOVA:QC5\|NjFOwG0>	NYH1b\|czOjJzNkm2NFE>
DIFI cells	MlK4R5l1d3SxeHnjbZR6KGG\|c3H5	NH;SVZk1KGSjeYO=	NHv2OoxEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBFUU[LIHPlcIx{KGGodHXyJFQh\GG7czDifUBxem:yaXTpeY0hcW:maXTlJJN1[WmwaX7nMYJie2WmIH\seY9zd22ndILpZ{BidmGueYPpd{whUUN3ME2wMlI{PSEQvF2=	NGmwb5QzOjF4OU[wNS=>
HT-29 cells	NXzuNGQ5S3m2b4TvfIlkcXS7IHHzd4F6	MX60JIRigXN?	MoHOR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gTHQuOjliY3XscJMh[W[2ZYKgOEBl[Xm\|IHL5JJBzd3CrZHn1cUBqd2SrZHWgd5RicW6rbnetZoF{\WRiZnz1c5JwdWW2cnnjJIFv[Wy7c3nzMEBKSzVyPUSuOlIh\|ryP	M1XGO\|IzOTZ7NkCx
RKO cells	MXzDfZRwfG:6aXPpeJkh[XO\|YYm=	M4XWXFQh\GG7cx?=	NHz2RXdEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBTU09iY3XscJMh[W[2ZYKgOEBl[Xm\|IHL5JJBzd3CrZHn1cUBqd2SrZHWgd5RicW6rbnetZoF{\WRiZnz1c5JwdWW2cnnjJIFv[Wy7c3nzMEBKSzVyPUWuN\|Uh\|ryP	Mn74NlIyPjl4MEG=
GXF251L cells	MW\DfZRwfG:6aXPpeJkh[XO\|YYm=	Mof5OEBl[Xm\|	M{DRbmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGdZTjJ3MVygZ4VtdHNiYX\0[ZIhPCCmYYnzJIJ6KHC{b4Dp[Il2dSCrb3Tp[IUhe3SjaX7pcocu[mG\|ZXSg[ox2d3KxbXX0dolkKGGwYXz5d4l{NCCLQ{WwQVEvPDhizszN	M2\IUlIzOTZ7NkCx
LIXF 575L cells	MV\DfZRwfG:6aXPpeJkh[XO\|YYm=	NHjjemI1KGSjeYO=	M3y2U2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGxKYEZiNUe1UEBk\WyuczDh[pRmeiB2IHThfZMh[nlicILvdIllcXWvIHnv[Ill\SC\|dHHpcolv\y2kYYPl[EBndHWxcn;t[ZRzcWNiYX7hcJl{cXNuIFnDOVA:Py5zODFOwG0>	NUTNXHBkOjJzNkm2NFE>
LXFA 289L cells	MWXDfZRwfG:6aXPpeJkh[XO\|YYm=	NHHmWGk1KGSjeYO=	NYPIfXlwS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hVFiIQTCyPFlNKGOnbHzzJIFnfGW{IESg[IF6eyCkeTDwdo9xcWSrdX2gbY9lcWSnIIP0ZYlvcW6pLXLhd4VlKG[udX;yc41mfHKrYzDhcoFtgXOrczygTWM2OD13Lke5JO69VQ>?	M{frelIzOTZ7NkCx
LXFA 526L	MlvjR5l1d3SxeHnjbZR6KGG\|c3H5	M{TCOVQh\GG7cx?=	NV3XcnYxS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hVFiIQTC1NlZNKGOnbHzzJIFnfGW{IESg[IF6eyCkeTDwdo9xcWSrdX2gbY9lcWSnIIP0ZYlvcW6pLXLhd4VlKG[udX;yc41mfHKrYzDhcoFtgXOrczygTWM2OD12LkKxJO69VQ>?	MnjTNlIyPjl4MEG=
LXFA 629L cells	MoLWR5l1d3SxeHnjbZR6KGG\|c3H5	MVm0JIRigXN?	M2i0fGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGxZTkFiNkK5UEBk\WyuczDh[pRmeiB2IHThfZMh[nlicILvdIllcXWvIHnv[Ill\SC\|dHHpcolv\y2kYYPl[EBndHWxcn;t[ZRzcWNiYX7hcJl{cXNuIFnDOVA:Oi56NzFOwG0>	NGXzS\|gzOjF4OU[wNS=>
LXFL 1121L cells	NHTabodEgXSxdH;4bYNqfHliYYPzZZk>	NEKyWnU1KGSjeYO=	NIr4T5REgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBNYE[OIEGxNlFNKGOnbHzzJIFnfGW{IESg[IF6eyCkeTDwdo9xcWSrdX2gbY9lcWSnIIP0ZYlvcW6pLXLhd4VlKG[udX;yc41mfHKrYzDhcoFtgXOrczygTWM2OD15LkezJO69VQ>?	NUDHNYZxOjJzNkm2NFE>
LXFL 529L cells	MXrDfZRwfG:6aXPpeJkh[XO\|YYm=	NH;5bnU1KGSjeYO=	MmrmR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUHhHVCB3MknMJINmdGy\|IHHmeIVzKDRiZHH5d{BjgSCycn;wbYRqfW1iaX;kbYRmKHO2YXnubY5oNWKjc3XkJIZtfW:{b33leJJq[yCjbnHsfZNqeyxiSVO1NF0{NjVzIN88US=>	MnjTNlIyPjl4MEG=
MCF7 cells	MnPpR5l1d3SxeHnjbZR6KGG\|c3H5	NEjGUlg1KGSjeYO=	MU\DfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDNR2Y4KGOnbHzzJIFnfGW{IESg[IF6eyCkeTDwdo9xcWSrdX2gbY9lcWSnIIP0ZYlvcW6pLXLhd4VlKG[udX;yc41mfHKrYzDhcoFtgXOrczygTWM2OD12LkizJO69VQ>?	MmDRNlIyPjl4MEG=
MDA231 cells	MYHDfZRwfG:6aXPpeJkh[XO\|YYm=	M{PRVFQh\GG7cx?=	MVvDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDNSGEzOzFiY3XscJMh[W[2ZYKgOEBl[Xm\|IHL5JJBzd3CrZHn1cUBqd2SrZHWgd5RicW6rbnetZoF{\WRiZnz1c5JwdWW2cnnjJIFv[Wy7c3nzMEBKSzVyPUeuO{DPxE1?	MXiyNlE3QTZyMR?=
OVXF 899L	MWLDfZRwfG:6aXPpeJkh[XO\|YYm=	NUKyXFZiPCCmYYnz	MULDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDPWnhHKDh7OVygZ4VtdHNiYX\0[ZIhPCCmYYnzJIJ6KHC{b4Dp[Il2dSCrb3Tp[IUhe3SjaX7pcocu[mG\|ZXSg[ox2d3KxbXX0dolkKGGwYXz5d4l{NCCLQ{WwQVMvOzVizszN	NGjTNmozOjF4OU[wNS=>
PAXF 546L cells	MUfDfZRwfG:6aXPpeJkh[XO\|YYm=	NVrCNZhnPCCmYYnz	NEDtSHhEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBRSViIIEW0Omwh[2WubIOgZYZ1\XJiNDDkZZl{KGK7IIDyc5Bq\Gm3bTDpc4Rq\GVic4ThbY5qdmdvYnHz[YQh\my3b4LvcYV1emmlIHHuZYx6e2m\|LDDJR\|UxRTZwMUKg{txO	MVeyNlE3QTZyMR?=
PANC1 cells	NFfU[4tEgXSxdH;4bYNqfHliYYPzZZk>	MUO0JIRigXN?	MmfXR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gVGFPSzFiY3XscJMh[W[2ZYKgOEBl[Xm\|IHL5JJBzd3CrZHn1cUBqd2SrZHWgd5RicW6rbnetZoF{\WRiZnz1c5JwdWW2cnnjJIFv[Wy7c3nzMEBKSzVyPUiuNVIh\|ryP	MU[yNlE3QTZyMR?=
22Rv1 cell	NH;PZlNEgXSxdH;4bYNqfHliYYPzZZk>	M3nOflQh\GG7cx?=	MkTsR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gNlJTfjFiY3XscJMh[W[2ZYKgOEBl[Xm\|IHL5JJBzd3CrZHn1cUBqd2SrZHWgd5RicW6rbnetZoF{\WRiZnz1c5JwdWW2cnnjJIFv[Wy7c3nzMEBKSzVyPU[uNFYh\|ryP	NEPZd4MzOjF4OU[wNS=>
DU145 cells	MYLDfZRwfG:6aXPpeJkh[XO\|YYm=	MU[0JIRigXN?	NV61VllXS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hTFVzNEWgZ4VtdHNiYX\0[ZIhPCCmYYnzJIJ6KHC{b4Dp[Il2dSCrb3Tp[IUhe3SjaX7pcocu[mG\|ZXSg[ox2d3KxbXX0dolkKGGwYXz5d4l{NCCLQ{WwQVIvQTlizszN	MnfWNlIyPjl4MEG=
LNCAP cells	MmjtR5l1d3SxeHnjbZR6KGG\|c3H5	MmK0OEBl[Xm\|	NY[yVmsxS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hVE6FQWCgZ4VtdHNiYX\0[ZIhPCCmYYnzJIJ6KHC{b4Dp[Il2dSCrb3Tp[IUhe3SjaX7pcocu[mG\|ZXSg[ox2d3KxbXX0dolkKGGwYXz5d4l{NCCLQ{WwQVMvPjhizszN	M2PhXVIzOTZ7NkCx
PC3M cells	Mk\ER5l1d3SxeHnjbZR6KGG\|c3H5	Mkn3OEBl[Xm\|	NYXX[2FwS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hWEN\|TTDj[YxteyCjZoTldkA1KGSjeYOgZpkheHKxcHnkbZVuKGmxZHnk[UB{fGGrbnnu[{1j[XOnZDDmcJVwem:vZYTybYMh[W6jbInzbZMtKEmFNUC9OE42PSEQvF2=	MUGyNlE3QTZyMR?=
NIH/3T3 cells	NWHuZ\|JqWHKxbHnm[ZJifGmxbjDhd5NigQ>?	MVu3NkBp	MWjBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IH3veZNmKE6LSD:zWFMh[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IF3UWEBie3OjeTygTWM2OD12LkOg{txO	NVvlfWd6OjJ3OUWxO\|c>
NCI-H1648 cell	NGrhXZFIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NHfrXVdKdmirYnn0bY9vKG:oIHj1cYFvKE6FST3INVY1QCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxRTBwMEK1OFQh\|ryP	M2i1eHNCVkeHUh?=
NMC-G1 cell	NVTQe3J2T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		Mn\VTY5pcWKrdHnvckBw\iCqdX3hckBPVUNvR{GgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2zMlU1PTBzIN88US=>	M1PEenNCVkeHUh?=
NTERA-S-cl-D1 cell	NXjaT5ViT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NXO1TmxiUW6qaXLpeIlwdiCxZjDoeY1idiCQVFXSRU1UNWOuLVSxJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9Ok4zPjV4MTFOwG0>	MWHTRW5ITVJ?
OCUB-M cell	NIHL[ohIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		M1vvRWlvcGmkaYTpc44hd2ZiaIXtZY4hV0OXQj3NJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4xPTd2IN88US=>	Mnv6V2FPT0WU
OS-RC-2 cell	MmDYS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NV;1SHJPUW6qaXLpeIlwdiCxZjDoeY1idiCRUz3SR{0zKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OS57OUG5PUDPxE1?	M3ewOXNCVkeHUh?=
OVCAR-4 cell	M2\VZmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NFvSVFVKdmirYnn0bY9vKG:oIHj1cYFvKE:YQ1HSMVQh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF06NjFzNke1JO69VQ>?	Ml\yV2FPT0WU
RL95-2 cell	NW\abG1qT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MnvmTY5pcWKrdHnvckBw\iCqdX3hckBTVDl3LUKgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2zMlE2PjdizszN	MYPTRW5ITVJ?
SW954 cell	NF3YSotIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		M3ezZ2lvcGmkaYTpc44hd2ZiaIXtZY4hW1d7NUSgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME21MlM6OjR3IN88US=>	MUfTRW5ITVJ?
SW962 cell	MWXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		MUfJcohq[mm2aX;uJI9nKGi3bXHuJHNYQTZ{IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;NT6zPVI1PSEQvF2=	MV3TRW5ITVJ?
TE-1 cell	NVjIOGV4T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		M1\WNGlvcGmkaYTpc44hd2ZiaIXtZY4hXEVvMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUWuNFIyPTlizszN	MVPTRW5ITVJ?
A253 cell	NH3RbppIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		MX;Jcohq[mm2aX;uJI9nKGi3bXHuJGEzPTNiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1{LkC0PFMh\|ryP	NVfseZg{W0GQR1XS
A388 cell	M2jl[2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7		MUnJcohq[mm2aX;uJI9nKGi3bXHuJGE{QDhiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1{LkC0PFMh\|ryP	NVXxZ\|VuW0GQR1XS
BB30-HNC cell	M1zO[Gdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		Ml3RTY5pcWKrdHnvckBw\iCqdX3hckBDSjNyLVjOR{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVEvQTd\|M{Wg{txO	MmDSV2FPT0WU
TE-12 cell	NVvURXl7T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NWTVfmpNUW6qaXLpeIlwdiCxZjDoeY1idiCWRT2xNkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvPzJ{NUig{txO	NEi0ZZVUSU6JRWK=
TE-5 cell	M4XRZ2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7		MlW1TY5pcWKrdHnvckBw\iCqdX3hckBVTS13IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;MD6yOFY2PCEQvF2=	NHi3enlUSU6JRWK=
TE-6 cell	NUKwclRoT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MmjkTY5pcWKrdHnvckBw\iCqdX3hckBVTS14IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;MD60PVA2PyEQvF2=	MorQV2FPT0WU
TE-8 cell	M1fBOmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		M4fjUmlvcGmkaYTpc44hd2ZiaIXtZY4hXEVvODDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUSuNFM4OyEQvF2=	M{no[HNCVkeHUh?=
TE-9 cell	NEL0[GFIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NYG5dJBoUW6qaXLpeIlwdiCxZjDoeY1idiCWRT25JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NU42PTJyMTFOwG0>	NVnHNopXW0GQR1XS
TK10 cell	M2rlN2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NV7Fb3ptUW6qaXLpeIlwdiCxZjDoeY1idiCWS{GwJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OE4yPjV{MjFOwG0>	NGj1SIpUSU6JRWK=
DSH1 cell	Mo\2S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		M2i4e2lvcGmkaYTpc44hd2ZiaIXtZY4hTFOKMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUCuNFk{QTZizszN	NFXFVY5USU6JRWK=
ECC12 cell	MWXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		M4fkU2lvcGmkaYTpc44hd2ZiaIXtZY4hTUOFMUKgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlA6OjNzIN88US=>	NG\DNm9USU6JRWK=
EKVX cell	M3LZdGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		MXLJcohq[mm2aX;uJI9nKGi3bXHuJGVMXlhiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1yLkS0PFc1KM7:TR?=	MmTPV2FPT0WU
HCC2218 cell	M{XaV2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7		MnXTTY5pcWKrdHnvckBw\iCqdX3hckBJS0N{MkG4JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4xPTN{NjFOwG0>	MYPTRW5ITVJ?
LB2241-RCC cell	NXrXcVFKT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MlTJTY5pcWKrdHnvckBw\iCqdX3hckBNSjJ{NEGtVmNEKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OS5zNUSwN{DPxE1?	NGDmfVdUSU6JRWK=
LB996-RCC cell	NHXnXJBIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		M1\WWmlvcGmkaYTpc44hd2ZiaIXtZY4hVEJ7OU[tVmNEKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OS5\|NkKyPEDPxE1?	M3jUfXNCVkeHUh?=
LC-1F cell	MVXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NWTJOoxKUW6qaXLpeIlwdiCxZjDoeY1idiCOQz2xSkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVEvOzh{NESg{txO	MmLxV2FPT0WU
LS-513 cell	MlrJS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		M{PnOWlvcGmkaYTpc44hd2ZiaIXtZY4hVFNvNUGzJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9N{41ODB2MTFOwG0>	NV;MO5pCW0GQR1XS

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	p-ErbB2 / t-ErbB2 / p-Akt / t-Akt / p-Erk / t-Erk; PubMed: 25238247 PLoS One Dose response of lapatinib and PD168393 on phosphorylation of ErbB2, AKT and ERK in Calu3 and SkBr3 cells in response to EGF treatment. p-ErbB2: phosphorylated ErbB2; t-ErbB2: total-ErbB2; p-AKT: phosphorylated AKT; t-AKT: total AKT; p-ERK: phosphorylated ERK; t-ERK: total ERK. pEGFR / EGFR / p-mTOR / mTOR / PARP / c-PARP ; PubMed: 28938602 Oncotarget SKBR3 and 78617 cells were treated with lapatinib as in panel A, then the expression of phospho-ErbB2 (Tyr1221/1222), ErbB2, phospho-EGFR (Tyr1068), EGFR, phospho-Akt (Ser473), Akt, phospho-Erk1/2 (Thr202/Tyr204), Erk2, phospho-mTOR (Ser2448), and mTOR were analyzed using Western blotting. All values are presented as the mean ± standard error (S.E.) (**p < 0.01).	25238247 28938602
Growth inhibition assay	Cell viability ; PubMed: 24947784 Oncotarget Huh7 (A), HepG2 (B), or HA22T (C) HCC cells were left untreated or treated with 0.1% DMSO (vehicle, D) or with DMSO containing various concentrations of lapatinib (1.25, 2.5, 5, or 10 μM) for 3 days. Relative amounts of viable cells were detected by MTS assay. O.D. values from DMSO-treated control cells were designated 100%.	24947784

In vivo

Oral administration of Lapatinib Ditosylate (~100 mg/kg) twice daily significantly inhibits the growth of BT474 and HN5 xenografts in a dose-dependent manner. ^[1]

Protocol

Kinase Assay:^[1]	- Collapse In vitro kinase assays: The IC50 values for inhibition of enzyme activity are generated by measuring inhibition of phosphorylation of a peptide substrate. The intracellular kinase domains of EGFR and ErbB2 are purified from a baculovirus expression system. EGFR and ErbB2 reactions are performed in 96-well polystyrene round-bottomed plates in a final volume of 45 μL. Reaction mixtures contain 50 mM 4-morpholinepropanesulfonic acid (pH 7.5), 2 mM MnCl₂, 10 μM ATP, 1 μCi of [γ³³P] ATP/reaction, 50 μM Peptide A [Biotin-(amino hexonoic acid)-EEEEYFELVAKKK-CONH2], 1 mM dithiothreitol, and 1 μL of DMSO containing serial dilutions of Lapatinib beginning at 10 μM. The reaction is initiated by adding the indicated purified type-1 receptor intracellular domain. The amount of enzyme added is 1 pmol/reaction (20 nM). Reactions are terminated after 10 minutes at 23°C by adding 45 μL of 0.5% phosphoric acid in water. The terminated reaction mix (75 μL) is transferred to phosphocellulose filter plates. The plates are filtered and washed three times with 200 μL of 0.5% phosphoric acid. Scintillation cocktail (50 μL) is added to each well, and the assay is quantified by counting in a Packard Topcount. IC50 values are generated from 10-point dose-response curves.
Cell Research:^[1]	- Collapse Cell lines: HFF, MCF-7, T47D, A-431, HN5, BT474, N87, CaLu-3, HB4a, and HB4a c5.2 Concentrations: Dissolved in DMSO, final concentrations ~100 μM Incubation Time: 72 hours Method: Cells are exposed to various concentrations of Lapatinib for 72 hours. Relative cell number is estimated using methylene blue staining. The absorbance at 620 nm is read in a Spectra microplate reader. Cell death and cell cycle analysis are assessed by propidium iodide staining and antibody detection of incorporated BrdUrd and staining with propidium iodide. (Only for Reference)
Animal Research:^[1]	- Collapse Animal Models: CD-1 nude female mice implanted s.c. with HN5 cells, and C.B-17 SCID female mice implanted s.c. with BT474 cells Formulation: Formulated in a vehicle of sulfo-butyl-ether-β-cyclodextrin 10% aqueous solution (CD10) Dosages: ~100 mg/kg Administration: Orally twice daily (Only for Reference)

References

[1] Rusnak DW, et al. Mol Cancer Ther, 2001, 1(2), 85-94.

Solubility (25°C)

In vitro	DMSO	100 mg/mL (108.05 mM)
	Water	Insoluble
	Ethanol	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 2% DMSO+30% PEG 300+ddH2O For best results, use promptly after mixing.	10mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Lapatinib (GW-572016) Ditosylate SDF

Molecular Weight	925.46
Formula	C₂₉H₂₆ClFN₄O₄S.2C₇H₈O₃S
CAS No.	388082-77-7
Storage	3 years -20°C powder
Storage	2 years -80°C in solvent
Synonyms	N/A

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-10-14)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT03075995	Unknown status	Other: hight-fat breakfast	Breast Cancer	Sun Yat-sen University	April 12 2017	Not Applicable
NCT02338245	Completed	Drug: ASLAN001\|Drug: Lapatinib\|Drug: Capecitabine	Metastatic Breast Cancer	Aslan Pharmaceuticals	December 29 2014	Phase 2
NCT02294786	Terminated	Drug: Lapatinib\|Drug: Capecitabine\|Drug: Octreotide	Cancer	Novartis Pharmaceuticals\|Novartis	December 17 2014	Phase 2
NCT02213042	Active not recruiting	Drug: Lapatinib\|Biological: Trastuzumab	Neoplasms Breast	Novartis Pharmaceuticals\|Novartis	October 24 2014	Phase 2
NCT01782651	Completed	Drug: Lapatinib plus capecitabine	Neoplasms Breast	GlaxoSmithKline	August 2014	--
NCT02158507	Active not recruiting	Drug: Combination of Veliparib + Lapatinib	Metastatic Triple Negative Breast Cancer	University of Alabama at Birmingham\|Scariot Foundation\|GlaxoSmithKline\|AbbVie	July 2014	Not Applicable

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
If I need to use S1028 for treating tumor-bearing mice with injection, how could I prepare the solution?
Answer:
S1028 Lapatinib Ditosylate can be dissolved in 2% DMSO/30% PEG 300/ddH2O at 10 mg/ml as clear solution.

HER2 Signaling Pathway Map

HER2 Inhibitors with Unique Features

Selective EGFR Inhibitor

Erlotinib HCl (OSI-744) : EGFR-selective, IC50=2 nM.
Most Potent EGFR Inhibitor

Afatinib (BIBW2992) : EGFR(wt), IC50=0.5 nM; EGFR(L858R), IC50=0.4 nM; EGFR(L858R/T790M), IC50=10 nM; HER2, IC50=14 nM.
FDA-approved EGFR Inhibitor

Lapatinib : Approved by FDA for breast cancer.
Newest EGFR Inhibitor

CO-1686 (AVL-301) ^New : Irreversible, mutant-selective EGFR inhibitor with K_i of 21.5 nM and 303.3 nM for EGFRL858R/T790M and EGFRWT, respectively.

Related HER2 Products

Erlotinib ^New

Erlotinib is an EGFR inhibitor with IC50 of 2 nM, >1000-fold more sensitive for EGFR than human c-Src or v-Abl.
R428 (BGB324，Bemcentinib) ^New

R428 (BGB324) is an inhibitor of Axl with IC50 of 14 nM, >100-fold selective for Axl versus Abl. Selectivty for Axl is also greater than Mer and Tyro3 (50-to-100- fold more selective) and InsR, EGFR, HER2, and PDGFRβ (100- fold more selective).
Pexidartinib (PLX3397) ^New

Pexidartinib (PLX3397) is an oral, potent mutil-targeted receptor tyrosine kinase inhibitor of CSF-1R, Kit, and Flt3 with IC50 of 20 nM, 10 nM and 160 nM, respectively. Phase 3.
AC480 (BMS-599626)

AC480 (BMS-599626) is a selective and efficacious inhibitor of HER1 and HER2 with IC50 of 20 nM and 30 nM, ~8-fold less potent to HER4, >100-fold to VEGFR2, c-Kit, Lck, MET etc. Phase 1.
CP-724714

CP-724714 is a potent, selective inhibitor of HER2/ErbB2 with IC50 of 10 nM, >640-fold selectivity against EGFR, InsR, IRG-1R, PDGFR, VEGFR2, Abl, Src, c-Met etc in cell-free assays. Phase 2.
Neratinib (HKI-272)

Neratinib (HKI-272) is a highly selective HER2 and EGFR inhibitor with IC50 of 59 nM and 92 nM in cell-free assays; weakly inhibits KDR and Src, no significant inhibition to Akt, CDK1/2/4, IKK-2, MK-2, PDK1, c-Raf and c-Met. Phase 3.
Sapitinib (AZD8931)

Sapitinib (AZD8931) is a reversible, ATP competitive inhibitor of EGFR, ErbB2 and ErbB3 with IC50 of 4 nM, 3 nM and 4 nM in cell-free assays, more potent than Gefitinib or Lapatinib against NSCLC cell, 100-fold more selective for the ErbB family than MNK1 and Flt. Phase 2.
Mubritinib (TAK 165)

Mubritinib (TAK-165) is a potent inhibitor of HER2/ErbB2 with IC50 of 6 nM in BT-474 cell; no activity to EGFR, FGFR, PDGFR, JAK1, Src and Blk in BT-474 cell line. Phase 1.
Tyrphostin AG 879

Tyrphostin AG 879 potently inhibits HER2/ErbB2 with IC50 of 1 μM, 100- and 500-fold higher selective to ErbB2 than PDGFR and EGFR.
Gefitinib (ZD1839)

Gefitinib (ZD-1839) is an EGFR inhibitor for Tyr1173, Tyr992, Tyr1173 and Tyr992 in the NR6wtEGFR and NR6W cells with IC50 of 37 nM, 37nM, 26 nM and 57 nM, respectively.

Features:A potent EGFR tyrosine kinase inhibitor.

Choose Your Country or Region

By Signaling Pathways

By product type

Lapatinib (GW-572016) Ditosylate

Cited by 75 Publications

Purity & Quality Control

Choose Selective HER2 Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Lapatinib (GW-572016) Ditosylate SDF

Bio Calculators

Molarity Calculator

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

Dilution Calculator

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-10-14)

Tech Support

Frequently Asked Questions

HER2 Signaling Pathway Map

HER2 Inhibitors with Unique Features

Related HER2 Products

Choose Your Country or Region

By Signaling Pathways

By product type

Lapatinib (GW-572016) Ditosylate

Cited by 75 Publications

Purity & Quality Control

Choose Selective HER2 Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Lapatinib (GW-572016) Ditosylate SDF

Bio Calculators

Molarity Calculator

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

Dilution Calculator

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-10-14)

Tech Support

Frequently Asked Questions

HER2 Signaling Pathway Map

HER2 Inhibitors with Unique Features

Related HER2 Products

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)